January 26, 2018 — LivaNova PLC and MicroPort Scientific Corp. announced the companies have entered into a binding ...

January 25, 2018 – Penumbra Inc. today announced results of the company-sponsored PROMISE Study, demonstrating real ...

January 25, 2018 – According to the latest market study released by Technavio, the global circulatory support devices ...

January 25, 2018 – Data presented at the Biotronik-sponsored symposium on the Orsiro drug-eluting stent (DES) ...

January 25, 2018 – In a large population study that was the first of its kind, researchers found that a simple tool not ...

Boston Scientific Corp. announced it has closed an investment and entered into an acquisition option agreement with Millipede Inc., a privately-held company that has developed the IRIS Transcatheter Annuloplasty Ring System for the treatment of severe mitral regurgitation (MR). Under the terms of the agreements, Boston Scientific has purchased a portion of the outstanding shares of Millipede along with newly issued shares of the company for a total consideration of $90M. Boston Scientific has the option to acquire the remaining shares of the company at any time prior to the completion of a first in human clinical study that meets certain parameters. Upon the completion of the clinical study, Millipede has the option to compel Boston Scientific to acquire the remaining shares of the company. Each company's option period expires by the end of 2019. Completion of this acquisition would result in an additional $325M payment by Boston Scientific at closing with a further $125M becoming payable upon achievement of a commercial milestone.